Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy

NCT02161380 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Leber's Hereditary Optic Neuropathy

Interventions

DRUG: injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),
DRUG: injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)
DRUG: injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)
DRUG: injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)

Sponsor

Byron Lam

Collaborators

[object Object]